TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01696591

Intervention type: BIOLOGICAL
Intervention: NEUROSTEM®-AD
Description: NEUROSTEM®-AD was administered to eligible subjects in the early part of the Phase I clinical study. In this follow-up study, no intervention will be performed.
Study: NCT04292106

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Spinach Extract (RSE)
Description: Oral capsules containing 2g of Red Spinach Extract will be consumed daily for 7 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsules will be taken consisting of maltodrextrin daily for 7 days
Study: NCT04104958

Intervention type: GENETIC
Intervention: qRTPCR (mRNA level).
Description: RNA extraction and RT-qPCR Protein extraction and western blotting ELISA assay

Intervention type: GENETIC
Intervention: qRTPCR (mRNA level).
Description: RNA extraction and RT-qPCR Protein extraction and western blotting ELISA assay
Study: NCT01838902

Intervention type: DRUG
Group type: OTHER
Intervention: DHA-PPQ
Description: Participants will receive a 3 day course of DHA-PPQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA-PPQ
Description: Participants will receive a 3 day course of DHA-PPQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA-PPQ
Description: Participants will receive a 3 day course of DHA-PPQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA-PPQ
Description: Participants will receive a 3 day course of DHA-PPQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQ (0.75)
Description: Participants will receive a single dose of PQ at 0.75mg base/kg body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQ (0.4)
Description: Participants will receive a single dose of PQ at 0.4mg base/kg body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQ (0.2)
Description: Participants will receive a single dose of PQ at 0.2mg base/kg body weight
Study: NCT00766584

Intervention type: OTHER
Intervention: Sleep apnea/hypopnea detection
Description: Simultaneous 24-hour ambulatory electrocardiogram and polygraphic recordings performed at home during a night.
Study: NCT02224391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Smoking Cessation Intervention
Description: Receive ABM training via a smartphone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Given via transdermal patch

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Nicotine Patch
Description: Given via transdermal patch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Undergo sham training
Study: NCT00977756

Intervention type: DRUG
Intervention: Atazanavir (ATV)
Description: 300 mg daily

Intervention type: DRUG
Intervention: Ritonavir (RTV)
Description: 100 mg daily, dosing by weight in Group I

Intervention type: DRUG
Intervention: Ritonavir (RTV)
Description: 100 mg daily, dosing by weight in Group I

Intervention type: DRUG
Intervention: Ritonavir (RTV)
Description: 100 mg daily, dosing by weight in Group I

Intervention type: DRUG
Intervention: Ritonavir (RTV)
Description: 100 mg daily, dosing by weight in Group I

Intervention type: DRUG
Intervention: Tenofovir (TDF)
Description: 300 mg daily

Intervention type: DRUG
Intervention: Etravirine (ETV)
Description: 200 mg BID

Intervention type: DRUG
Intervention: Etravirine (ETV)
Description: 200 mg BID

Intervention type: DRUG
Intervention: Darunavir (DRV)
Description: Dosing by weight

Intervention type: DRUG
Intervention: Maraviroc (MVC)
Description: 150 mg BID in groups J and K; 600 mg BID in group L

Intervention type: DRUG
Intervention: Maraviroc (MVC)
Description: 150 mg BID in groups J and K; 600 mg BID in group L

Intervention type: DRUG
Intervention: Maraviroc (MVC)
Description: 150 mg BID in groups J and K; 600 mg BID in group L

Intervention type: DRUG
Intervention: Lopinavir/ritonavir (LPV/r)
Description: Coformulation of 400 mg lopinavir and 100 mg ritonavir, taken twice daily
Study: NCT01715974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF group
Description: 30 micrograms/day of GM-CSF from the day of embryo transfer through the day of beta HCG test

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CONTROL
Description: saline infusion every day from the day of embryo transfer through the day of beta HCG test
Study: NCT02857426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT03587142

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspirone
Description: Buspirone tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic buspirone 10 mg tablet
Study: NCT00677443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 & Oxaliplatin
Description: S-1 and Oxaliplatin : S-1 80 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine & Oxaliplatin
Description: COX : Capecitabine 1000 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
Study: NCT04772846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral tablet
Description: Oral 250mg chloroquine tablets
Study: NCT03847753

Intervention type: OTHER
Intervention: Substance Use Disorders
Description: Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.

Intervention type: OTHER
Intervention: Schizophrenia Disorders
Description: Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.

Intervention type: OTHER
Intervention: Mood disorders
Description: Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.

Intervention type: OTHER
Intervention: Neurotic disorders
Description: Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.

Intervention type: OTHER
Intervention: Eating Disorders
Description: Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.

Intervention type: OTHER
Intervention: Personality Disorders
Description: Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.

Intervention type: OTHER
Intervention: Intellectual Disorders
Description: Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.

Intervention type: OTHER
Intervention: Developmental Disorders
Description: Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.

Intervention type: OTHER
Intervention: Behavioral Disorders
Description: Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
Study: NCT03025139

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Attend survivorship education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Attend survivorship education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Meditation Therapy
Description: Attend mindfulness meditation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Meditation Therapy
Description: Attend mindfulness meditation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04772846

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo tablets
Study: NCT05908123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Blank Center CARE Model(TM) for Individuals who Stutter
Description: The over-arching goal of the Blank Center CARE Model is to ensure individuals who stutter communicate effectively, advocate for themselves in a manner that maintains agency, and ensure their quality of life does not depend on producing, or attempting to control, stuttered speech.
Study: NCT04697641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg
Description: Clarithromycin 500 mg twice a day for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 1000 MG
Description: Amoxicillin 1000mg twice a day for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40mg
Description: Pantoprazole 40 mg or equivalent for eight weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole 40mg
Description: Pantoprazole 40 mg or equivalent for eight weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosulpiride
Description: Levosulpiride 25 mg as and when required before meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acotiamide
Description: Acotiamide 100mg as when required before meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itopride
Description: Itopride 50mg as when required before meals
Study: NCT04570865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioMEMS
Description: The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.
Study: NCT04793529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Cholecalciferol injection
Study: NCT02751450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stannous Fluoride dentifice
Description: Experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm)

Intervention type: OTHER
Group type: OTHER
Intervention: Sodium Monofluorophosphate dentifrice
Description: Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
Study: NCT02640950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroStar TMS
Description: Transcranial Magnetic Stimulation
Study: NCT03734328

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft
Description: * anesthesia of the palatal mucosa~* subepithelial connective tissue graft harvesting~* suturing (5/0 silk suture)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: connective tissue graft
Description: * anesthesia of the palatal mucosa~* subepithelial connective tissue graft harvesting~* suturing (5/0 silk suture)
Study: NCT00263328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Standard of care
Study: NCT03734328

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft&PRF
Description: anesthesia of the palatal mucosa subepithelial connective tissue graft harvesting~-suturing (5/0 silk suture)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: connective tissue graft&PRF
Description: anesthesia of the palatal mucosa subepithelial connective tissue graft harvesting~-suturing (5/0 silk suture)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft&PRF
Description: * taking blood from patient~* centrifuging blood~* obtain PRF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: connective tissue graft&PRF
Description: * taking blood from patient~* centrifuging blood~* obtain PRF
Study: NCT03582982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eccentric overload exercise
Description: 12 weeks of 2x per week of the following eccentric exercises: squat, shoulder press, row, and bicep curl.
Study: NCT03770962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two midwives
Description: Two midwives will be present during the active phase of the second stage and the birth of the baby. Midwife no 1 is the midwife who has been responsible for the care of the woman and midwife no 2 will assist her.
Study: NCT00263328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: CP-690,550 5 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: CP-690,550 10 mg BID
Study: NCT03014297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosbretabulin
Description: fosbretabulin
Study: NCT01404754

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose (inactive placebo)
Description: Placebo in an equivalent weight to midomafetamine HCl will be administered in identical appearing capsules during one of two experimental sessions. An equivalent to the initial and supplemental dose will exist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midomafetamine HCl
Description: 120 mg midomafetamine HCl will be administered in opaque capsules at the outside of one of two experimental sessions, and upon mutual agreement between the investigator and participant, 40 mg may be administered 1.5 to 2.5 hours later.
Study: NCT02698657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP5094
Description: Intravenous (IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous (IV)
Study: NCT01609543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150 mg orally daily, until disease progression, unacceptable toxicity or withdrawal due to any reason
Study: NCT00467727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase Contrast Mammography
Description: Standard and magnification views
Study: NCT04426864

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Aerobic Plus Stretching Exercises
Description: An exercise prescription was developed for each woman based on the data acquired from the baseline treadmill exercise test. Target HR corresponding to values of 50-70 % ergospirometric VO2max (moderate-intensity) was determined by the submaximal treadmill test. The participants were instructed to perform their exercises at 50 % of VO2max for six weeks. At seventh their exercise intensity was increased to target HR corresponding to 70 % of VO2max. HR was monitored by a Polar HR monitor (Polar Beat, Port Washington, NY). Stretching exercises were performed at the beginning and end of each exercise session. Each muscle group exercise was performed 3-4 times and each repeat was 30 seconds long. The muscle groups which were involved in stretching exercises were upper trapezius, rhomboid, hip flexor, hamstring, pectoral, piriformis, quadriceps, gastrocnemius, soleus, levator scapulae, hip adductor and tensor fasciae late muscles. The exercise program was applied 3 days a week for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Resistance Plus Stretching Exercises Group
Description: According to the data obtained from 1-RM tests, an exercise prescription was developed for each woman. The participants were instructed to perform their exercises with 50% of 1-RM for six weeks. In the 7. week, weights were increased to 70-80% of 1-RM. The number of sets increased progressively (10 repetitions per set; 1 set in the first two weeks; 2 sets in the 3rd and 4th week; 3 sets in the 5th and 6th week). The muscle groups which were involved in resistance exercises were bilateral biceps, deltoid, trapezius, pectorals, serratus anterior, latissimus dorsi, levator scapulae, rhomboid, gluteal, quadriceps, hip adductor and abductor, hamstring, gastrocnemius and abdominal muscles. Stretching exercises were performed at the beginning and end of each exercise session. Each muscle group exercise was performed 3-4 times and each repeat was 30 seconds long. Stretching exercises were given for the muscle groups they worked on. The exercise program was applied 3 days a week for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Stretching Exercises Group
Description: Each exercise was described to the patient by visually. For each muscle group exercise was performed for 3-4 times and each repeat was 30 seconds long. The muscle groups which were involved in stretching exercises were upper trapezius, rhomboid, hip flexor, hamstring, pectoral, piriformis, quadriceps, gastrocnemius, soleus, levator scapulae, hip adductor and tensor fasciae late muscles. Exercise program was applied 3 days in a week during 12 weeks. Each participant was called every 2 weeks to maintain compliance.
Study: NCT02677025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Young Women's Health CoOp (YWHC)
Description: Participants in this group will participate in two workshops of the young woman-focused intervention about HIV/STIs (sexually transmitted infections), sexual behaviors, alcohol and other drug use, violence, communication skills, and other issues. Participants will develop personalized risk reduction action plans at the end of each workshop session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Counseling/Testing
Description: Participants will be tested for HIV and if positive will receive counseling in accordance with national standards.
Study: NCT00708435

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Beriplex® P/N (Kcentra)
Description: Intravenous infusion, dosage depending on baseline INR, amount of coagulation factor IX and body weight

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh frozen plasma
Description: Intravenous Infusion, dosage depending on baseline INR and body weight
Study: NCT03540875

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed loop anesthesia
Description: Propofol and Remifentanil are administered automatically using a closed-loop system.~The goal of this study is to compare manual titration versus automated titration of propofol and remifentanil in adult patients undergoing surgery guided by the electro-cortical activity. The aim in both group is to maintain the qCon in the range 40-60 during induction and maintenance of general anesthesia using the propofol in TCI mode. But also the qNox in the range 40-60 using remifentanil. The controller is based on a Proportional-Integral-derivative algorithm which steers a target to the pumps during induction and maintenance of general anesthesia.

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: The dosage is modified automatically by the device or according to the new medical prescription.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The dosage is modified automatically by the device or according to the new medical prescription.
Study: NCT03933696

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tailored Lighting Intervention
Description: Lighting Intervention either Active or Placebo

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Tailored Lighting Intervention
Description: Lighting Intervention either Active or Placebo
Study: NCT03540875

Intervention type: DRUG
Group type: OTHER
Intervention: Remifentanil
Description: The dosage is modified automatically by the device or according to the new medical prescription.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: The dosage is modified automatically by the device or according to the new medical prescription.
Study: NCT01210521

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D, (2000IU) will be administered orally, once a day, for one month.
Study: NCT02186587

Intervention type: DEVICE
Group type: OTHER
Intervention: ConforMIS custom total knee
Description: Total knee arthroplasty using ConforMIS custom total knee system with follow-up at 6 months
Study: NCT01914471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Students for Nutrition and eXercise
Description: These schools received the entirety of Students for Nutrition and eXercise, a middle-school-based obesity-prevention intervention combining school-wide environmental changes, multimedia, encouragement to eat healthy school cafeteria foods, and peer-led education and marketing
Study: NCT04019613

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung ultrasound
Description: Lung ultrasound will be performed at baseline (resting), prior to exercise with passive leg elevation, after 1.5 minutes of 20 Watts exercise, during each subsequent stage, at peak workload and at 1 minute recovery. Pulmonary thermodilution will be performed at rest, peak stress and at 1 minute recovery.
Study: NCT02241083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no medication